We have previously established induced pluripotent stem cell (iPSC) models of Huntington's disease (HD), demonstrating CAG-repeat-expansion-dependent cell biological changes and toxicity. However, the current differentiation protocols are cumbersome and time consuming, making preparation of large quantities of cells for biochemical or screening assays difficult. Here, we report the generation of immortalized striatal precursor neurons (ISPNs) with normal (33) and expanded (180) CAG repeats from HD iPSCs, differentiated to a phenotype resembling medium spiny neurons (MSN), as a proof of principle for a more tractable patient-derived cell model. For immortalization, we used co-expression of the enzymatic component of telomerase hTERT and conditional expression of c-Myc. ISPNs can be propagated as stable adherent cell lines, and rapidly differentiated into highly homogeneous MSN-like cultures within 2 weeks, as demonstrated by immunocytochemical criteria. Differentiated ISPNs recapitulate major HD-related phenotypes of the parental iPSC model, including brain-derived neurotrophic factor (BDNF)-withdrawal-induced cell death that can be rescued by small molecules previously validated in the parental iPSC model. Proteome and RNA-seq analyses demonstrate separation of HD versus control samples by principal component analysis. We identified several networks, pathways, and upstream regulators, also found altered in HD iPSCs, other HD models, and HD patient samples. HD ISPN lines may be useful for studying HD-related cellular pathogenesis, and for use as a platform for HD target identification and screening experimental therapeutics. The described approach for generation of ISPNs from differentiated patient-derived iPSCs could be applied to a larger allelic series of HD cell lines, and to comparable modeling of other genetic disorders.
Pubmed ID: 34296279 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This unknown targets rabbit IgG (H+L) F(ab) 2 Fragment
View all literature mentionsThis unknown targets IgG (H+L)
View all literature mentionsThis unknown targets GABA
View all literature mentionsThis monoclonal targets Bcl-11B
View all literature mentionsThis polyclonal targets DARPP-32 (H-62)
View all literature mentionsThis monoclonal targets Tuj 1
View all literature mentionsThis monoclonal targets MAP-2 (Microtubule Associated Protein, MAP-2A and -2B)
View all literature mentionsThis monoclonal targets nestin (10c2)
View all literature mentionsThis monoclonal targets MEIS2
View all literature mentionsThis polyclonal targets GSX2
View all literature mentionsThis monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH
View all literature mentionsThis polyclonal targets CAMK4
View all literature mentionsThis monoclonal targets Calbindin
View all literature mentionsThis monoclonal targets NeuroD (D90G12) Rabbit mAb
View all literature mentionsThis monoclonal targets Polyglutamines
View all literature mentionsThis monoclonal targets Huntingtin Protein, aa 181-810
View all literature mentionsThis monoclonal targets MAP-2 (Microtubule Associated Protein, MAP-2A and -2B)
View all literature mentionsThis polyclonal targets DARPP-32 (H-62)
View all literature mentions